ViaCyte

about viacyte viacyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. viacyte’s product candidates are based on directed differentiation of pluripotent stem cells into pec-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. viacyte demonstrated that when effectively engrafted, pec-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. to accelerate and expand its efforts, viacyte has established collaborative partnerships with leading companies including crispr therapeutics and w.l. gore & associates. about viacyte’s pipeline the pec-direct product candidate, currently being evaluated in the clinic, delivers viacyte’s pec-01 cells (pancreatic islet progenitor cells) in a non-immunoprotective device and is being developed for type 1 diabetes patients who have hypoglycemia unawareness, extreme glycemic lability, and/or recurrent severe hypoglycemic episodes. the pec-encap (also known as vc-01) product candidate, also undergoing clinical evaluation, delivers the same pancreatic islet progenitor cells but in an immunoprotective device. pec-encap is being developed for all patients with type 1 diabetes. in collaboration with crispr therapeutics, viacyte is developing immune-evasive stem cell lines from its proprietary cyt49 cell line. these immune-evasive stem cell lines, which are being used in the pec-qt program, have the potential to further broaden the availability of cell therapy for all patients with insulin-requiring diabetes, type 1 and type 2. in addition, a pluripotent, immune evasive cell line has the potential to be used to produce any cell in the body, thus enabling many other potential indications.

查找电子邮件地址

使用 tomba.io 快速尝试一下。 tomba.io.

从列表中查找电子邮件地址从 Google 开始